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Although thyroid cancers are not among common malignancies, they rank as the first prevalent endocrine cancers
in human. According to the results of published studies it has been shown the gradual progress from normal to
the neoplastic cell in the process of tumor formation is the result of sequential genetic events. Among them we
may point the mutations and rearrangements occurred in a group of proto-oncogenes, transcription factors and
metastasis elements such as P53, RAS,RET,BRAF, PPARγ and Fascin. In the present article,we reviewed the most
important essential genes in thyroid cancers, the role of epithelial mesenchymal transition and Fascin has been
highlighted in this paper.
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Thyroid cancer is considered as a rare malignancy which
accounts for 1 to 2% of different type cancers. The an-
nual occurrence rate of thyroid cancer in different parts
of the world is reported to be about 0.5 to 10 in every
100,000 persons; yet, this cancer is considered as the
most prevalent malignancies of the endocrine system
[1-3]. Various studies indicate that women are 2–4 times
more likely to suffer from the cancer [4]. There is no dif-
ference between the incidence of thyroid cancer between
men and women before menarche and after menopause,
suggesting that the increased risk of developing thyroid
neoplasia in women at child bearing age could be se-
condary to the effects of estrogen or other pregnancy-
related factors. Moreover, the rate of developing thyroid
cancers increases significantly after pregnancy, espe-
cially, in the last four months of pregnancy. However, it
should be noted that, those consuming contraceptive
pills or other external sources of estrogen are not at an
increased risk of developing thyroid cancers [5]. Positive
family history of thyroid cancer is reported in 3-5% of
the affected cases [3,6,7]. Apart from gender and genetic
factors, the body size [8], race [9], geographical distribu-
tion [10,11] and the amount of consumed iodine [12]
also influence the risk of developing thyroid cancers.* Correspondence: v.haghpanah@gmail.com
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reproduction in any medium, provided the orWhile thyroid cancer is reported at any age, the risk of
developing the malignancy increases after the age of 30.
Many believe thyroid cancer becomes more invasive
with aging [13].
In the majority of the cases, cancer presents as asymp-
tomatic thyroid nodules. In certain cases, however, pa-
tients complaint of pain in the neck, lymphadenopathy,
and bone and lung involvement.
While thyroid nodules are found in approximately 10%
of the people in each society, only 4-5% of the reported
cold nodules are malignant [3,14]. In countries with iodine
deficiency,where iodine prophylaxisis common, palpable
thyroid nodules are reported in 4-5% of the population
[15]. Although more than 90% of thyroid nodules in the
general population are benign, some of these nodules
might be malignant in nature as about 0.4% of the entire
mortalities from cancer occur in those with thyroid malig-
nancies [13].
Pathological analysis of thyroid cancers indicates that
four types of thyroid cancers, namely papillary, follicular,
anaplastic and medullary thyroid cancers, are more
prevalent. The first three are of the follicular cell origin,
whereas the medullary carcinoma originates from para-
follicular cells (C Cells) [2,16].Papillary thyroid carcinoma (PTC)
Papillary carcinoma is the most prevalent type of thyroid
cancer, reported in about 70% of those with thyroid ma-
lignancies. Half of the cases present before the age of 40;Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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decades of life. The cancer is 2–3 times more frequently
reported in women. High rates of this type of thyroid can-
cer are seen in those exposed to high dose X-radiation
during childhood. The cases of sporadic thyroid cancer
account for 95% of the sufferers and only 5% of the cases
are hereditary [17].
Lymph node involvement is common in papillary car-
cinoma, with metastasis to neck lymph nodes and con-
tiguous tissues reported in 50% and 25% of the cases,
respectively. Compared to other thyroid carcinomas,
metastasis via blood and particularly lung involvement is
more prevalent in papillary carcinoma. This comes while
involvement of the bones of the central nervous system
and other organs is also possible. With respect to prog-
nosis, papillary carcinomas tend to grow very slowly
compared with other types of thyroid cancer. In other
words, over 90% of the sufferers now survive for more
than ten years; in 80% of them the life span is about
20 years [18].
Follicular thyroid carcinoma (FTC)
Follicular carcinomas are less prevalent than the papil-
lary type and account for only 15% of thyroid malignan-
cies. Most follicular carcinomas manifest in old ages and
after the age of 52. The risk is 2–5 times higher in
women. The cancer mainly presents as single cold nod-
ules. In this stage, the lymph nodes are not yet involved.
This comes while distant metastasis in lungs and bones
are common in many sufferers [19]. Compared with
papillary carcinoma, follicular carcinoma has a poorer
prognosis, with only 30% of the sufferers living for up to
10 years after the primary treatment [18].
Anaplastic thyroid carcinoma (ATC)
This carcinoma accounts for about 2% to 5% of thyroid
malignancies. It is considered as a highly aggressive and
lethal thyroid carcinoma. It can be seen at any age; how-
ever, it is more common among those aged between 60
and 70. Women are 5 times more vulnerable of develo-
ping the cancer [20]. In 50% of the cases, anaplastic carci-
noma may occur following a long-term history of goiter,
thyroid adenoma, papillary or follicular carcinoma; its risk
of becoming malignant, however, is rather low.
The cancer mainly presents with a rapidly growing
neck mass [21]. The malignancy has the poorest progno-
sis among primary thyroid neoplasms as the afflicted
subjects die between 6 to 8 months after diagnosis. The
tumor is treatable if diagnosed and treated in early
stages [22].
Medullary thyroid carcinoma (MTC)
Medullary carcinoma accounts for 10% of thyroid malig-
nancies. It is the most invasive type of cancer, on whichiodine and chemotherapy are not effective. Surgery re-
mains the only way to treat such cases; however, in cases
experiencing recurrence, no successful treatment has
been reported. On average, 65% of the patients may sur-
vive for 10 years [23].
The cancer is mainly characterized with calcitonin se-
cretion. The cases of sporadic thyroid cancer account
for 80% of the sufferers. Medullary Thyroid Carcinoma
mainly occurs in the 5th and 6th decades of life and in
75% to 95% of the cases present as a single nodule.
Unlike papillary, follicular and anaplastic carcinomas
that originate from follicular cells, medullary carcinomas
are from para-follicular cells (C-cells), located at the
junction of the upper third and the lower two-third of
the thyroid lobes [24]. The majority of such tumors
therefore are observed in this area. In 50% of the pa-
tients, latero-cervical lymph nodes are involved. In 15%
of the patients, the symptoms of pressure imposed on
esophagus and upper parts of the pulmonary system are
reported. Metastasis is reported in 5% of the patients.
Age at the time of diagnosis is the most important
diagnostic factor in these patients.
In 20% of the cases, genetic is the most important pre-
disposing factor and medullary cancer is mainly known
as an autosomal dominant disorder [25]. Three kinds of
hereditary medullary thyroid cancers are known:
– Multiple Endocrine Neoplasia 2A (MEN 2A)
– Multiple Endocrine Neoplasia 2B (MEN 2B)
– Familial Medullary Thyroid Carcinoma (FMTC)
Most important genetic factors involved in different types
of thyroid malignancies
Molecular mechanisms involved in the development of
such malignancies are not well known. This comes while
existing studies in this regard have reported that the oc-
currence of 6 or 7 mutations in certain proto-oncogenes
during a period of 20 to 40 years is necessary to induce
tumor growth [26].
Two families of genes are involved in the proliferation
of healthy cells: Proto-oncogenes increase cellular prolif-
eration and tumor suppressor genes stop cell division.
The development of thyroid tumors is reported to be
secondary to the activation of mutated oncogenes or
suppression of tumor suppressor genes or both [27].
P53
P53 is a tumor suppressor gene, which regulates physio-
logic cell growth through inducing G1-phase cell cycle
arrest [28]. Point mutation of this gene is considered as
the most prevalent change linked with such tumors,
particularly anaplastic thyroid carcinomas [29,30]. The
presence of these mutations determine tumor inva-
sion. Freeman et al. reported that any changes in the
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therefore, measuring the rate of P53 expression can
be considered as a diagnostic marker in identifying
invasive tumors and thus patients with poor prognosis
[29]. P53 mutations are reported in 11.1% of patients
with papillary carcinoma, 14.3% with follicular carcin-
oma and 63% with anaplastic carcinoma (in some
studies mentioned to be between 75 to 83.3%). Con-
sidering the fact that P53 mutation or increased ex-
pression of the protein is more common in anaplastic
carcinoma compared with other differentiated carcin-
omas, it could be concluded that the change in the
expression rate may influence the transformation of
differentiated carcinomas into the anaplasticones.
Therefore, studying the expression of p53 can help
identify indistinguishable thyroid cancers [31].
RAS
RAS family consists of three genes
 N-RAS on Chromosome 1
 H-RAS on Chromosome 11
 K-RAS on Chromosome 12
These genes are linked to the synthesis of a group of
21 kDa proteins [32] that play an important role in cell
growth and differentiation. Point mutation in any of
these genes may result in the transformation of proto-
oncogenes to oncogenes, and consequently the develop-
ment of cancer [33]. In more than 30% of human tu-
mors, mutation is reported in the 12th, 13th and 61th
codons of RAS proto-oncogene [34]. It is to be noted
that mutation in a given allele of these genes is sufficient
for the activation of proto-oncogenes [33]. The activa-
tion of RAS oncogenes is reported in many of benign
and malignant thyroid tumors [35]. Despite the fact that
there are a few such tumors, the prevalence of RAS mu-
tations in thyroid neoplasia, particularly follicular and
invasive cancers, seems to be high [36]. This comes
while no significant correlation has been reported be-
tween increased RAS protein expression and the higher
rate of distinction or metastasis [37]. RAS proto-
oncogene mutations are reported in 20% to 60% of thy-
roid tumors, especially in follicular cancers [36]. Such
mutations are also more prevalent in areas where there
is little iodine in the diet [38]. Activated RAS protein is
reported in 20% of patients suffering from papillary car-
cinoma, 53% of those with follicular carcinoma and 6 to
50% of subjects diagnosed with anaplastic carcinoma
[39-44].
RET
Pericentric inversion of chromosome 10 involving the
RET (ret proto-oncogene) gene at chromosome 10q11 isknown to increase expression of the RET gene. The acti-
vation of this oncogene also encodes tyrosine kinase re-
ceptor [45].
RET was first discovered by Fusco et al. The activation
of the gene is reported in 25% of patients with papillary
thyroid cancer [46]. Papillary thyroid cancer is character-
ized by chromosal rearrangements, through which the
promoter and the primary sequences of a genes (R1α-
NcoA4- RFG5- hTIF1- CCDC6- RFG7/hTIFR) are trans-
ferred to the terminal sequences of the RET gene,
developing a fusion gene. RET/PTC fusion gene encodes
a permanently active receptor [47]. Many believe these
rearrangements are the initiator of tumor formation in
individuals with papillary carcinoma [48]. In other
words, the expression of RET/PTC oncogene is common
in papillary thyroid cancer cells (77% in concealed papil-
lary carcinoma vs. 47% in apparent papillary carcinoma)
[49]. RET proto-oncogene mutations are also connected
with syndromes with dominant inheritance such as
MEN 2A, MEN 2B and familial medullary thyroid
cancer.
Nowadays, RET point mutations are applied as
markers for identifying hereditary and sporadic Medul-
lary Thyroid Carcinoma (MTC) [50,51]. In FMTC and
MEN 2A, the well-known mutations in exon 10 (cor-
dons 609, 611, 618 and 620) or 11 (codon 634) entangles
the extra-cellular area of RET receptor [52,53].
Duplication/insertion mutations in exon 11 are
reported in rare cases of MEN 2A [54,55]. RET germ line
mutations are also reported in exon 13 (cordons 768,
790 and 791), 14 (codons 804 and 844) and 15 (codon
891) of patients with FMTC [56]. While a missense mu-
tation in codon 918 is reported in more than 90% of pa-
tients with MEN 2B, mutation at codon 881 in exon 15is
a rare finding in these patients [57]. Such variants are
mainly linked with the phenotype of MEN 2B [58]. The
accurate prevalence of RET/PTC rearrangement is not
well known, as the variant is seen in 2.5 to 34.5% of
these patients [59].
Somatic changes of RET proto-oncogene are also dis-
covered in 30 to 60% of sporadic PTC tumors, but rarely
in familial cases [60]. The abovementioned
rearrangements are the only genetic variants reported in
PTC patients [49].
BRAF
In mammalian cells, three isoforms of serine threonine
kinase RAF, including ARAF, BRAF and CRAF (RAF1)
with different tissue expression rates, are reported [61].
BRAF, located on chromosome7 (7q34), is responsible
for controlling cell proliferation and differentiation
through the MAP kinase pathway [62]. Inappropriate
and abnormal activity of such a pathway may result in a
pro-mitogenic force, causing abnormal distinction and
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tations are the most prevalent genetic abnormality
reported in papillary thyroid carcinoma. It is, however,
reported in up to 50% of individuals with anaplastic car-
cinoma. In about 95% of the cases, mutation of nucleotide
1799, results in the substitution of valin with glutamate at
residue 600 (V600E). Such a mutation, however, is not
observed in distinguishable follicular and medullary neo-
plasia sufferers [64-67]. Abundance of BRAF mutations in
papillary thyroid carcinoma puts forward this matter that
suppressing the activity of BRAF can help develop new
treatment modalities for the disease [68].
Nambaet al pointed out the link between BRAF muta-
tion and papillary thyroid carcinoma [69]. Similarly,
Webb et al. reported the involvement of MAPK/MEK/
RAF pathway in metastasis and tumor growth [70]. Such
results suggest that the analysis of BRAF mutations may
pave the way for the early diagnosis of patients with pap-
illary carcinoma [69].
Simultaneous mutation in RAS and BRAF has never
been reported. This finding is in line with data extracted
from other tumor models [71]. Moreover, considering
the fact that RAS proto-oncogene mutation is only
reported in 20% of patients with papillary carcinoma,
studying the simultaneous occurrence of RAS and BRAF
mutation is not of much importance [72]. However, fur-
ther studies are needed to determine the importance of
RET/PTC and BRAF mutations in tumorigenesis [71].
PPARγ
For the first time in 2000, Kroll et al. showed the re-
arrangement of PAX8 and PPARγ in individuals with
follicular thyroid carcinoma [73]. PPARγ (Proxisome
Proliferator Activated Receptor Gamma) is a tran-
scription factor involved in lipid metabolism and cell
differentiation [74]. PAX8 (Paired Box Gene 8), the
transcription factor in thyroid tissues, controls expres-
sion of certain proteins such as TSHR, thyroid perox-
idase, and Sodium-Iodine transporter [75]. Protein
arising from such fusion (PAX8/PPARγ) has the same
function as that of PPARγ; however, its characteristics
are different from PAX8 and PPARγ [76]. Recent
studies in this field demonstrated PAX8/PPARγ re-
arrangement in 25%-63% of patients with follicularTable 1 Most prevalent mutations noted in different types of
Thyroid tumor type Mutation
P53 RAS RET BRAF
Papillary Carcinoma + + - +
Follicular Carcinoma + + - -
Anaplastic Carcinoma + + - +
Medullary Carcinoma - - + -carcinoma [77] and 37.5% of those suffering from papillary
carcinoma [78]. (Table 1).
Metastasis
Metastasis is a complex biological process that requires
cancer cells to be separated from adjacent cells in a way
that they could target the extracellular matrix (ECM)
and the basilar membrane, and enter blood circulation.
Such cells escape the immune system and reach farther
tissues, resulting in the formation of secondary tumors
at other locations. The process is associated with in-
creased risk of death from cancer. Much research has
been conducted to study the pathology and treatment of
metastasis, especially, with respect to molecular mecha-
nisms. Epithelial mesenchymal transition (EMT) is an
important part of the metastatic cascade [79]. They initi-
ate metastasis and thus have attracted many researchers
studying cancer and metastasis.
Fascin, as one of the proteins involved in metastasis, is
very important in such a process. In mammalians, Fascin
has three isoforms:
◦ Fascin-1, specific for the mesenchyme and neural
system, is situated at 7p22 [80].
◦ Fascin-2 islimited to photo-receptor cells in the eye.
Its encoding gene is in 17q25 [81].
◦ Fascin-3 found in testis. Its locus is in 7q31 [82].
From among the mentioned proteins, Fascin-1 binds
to actin filaments and may form cellular protrusions
such as filopodia and lamelipodia. The formation of such
structures can result in higher rate of invasion and me-
tastasis [83]. Fascin-1 is a genetically conserved protein
(493 amino acids, 55KD), linked with actin filaments in
the cytoplasm from two different sites. Through arran-
ging these filaments, Fascin-1 can organize cell move-
ment [84]. Immunohistochemistry (IHC) and Tissue
Microarray (TMA) studies of various cancers, especially
metastatic lung and pancreatic cancer, have revealed in-
creased expression of Fascin-1 in cancerous tissues cells.
For instance, healthy lung cells have no Fascin-1. This
comes while IHC studies showed increased expression
of Fascin-1 in 89% of such cells if they become cancer-
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from among 57 persons suffering from pancreatic can-
cer, 95% had increased Fascin-1 expression. In another
study, conducted two years later, TMA studies on 68
people suffering from this cancer showed increased ex-
pression of such protein in 97% of the cases.
IHC studies have confirmed increased Fascin-1 expres-
sion in papillary, follicular and anaplastic thyroid cancer.
On the other hand, the expression of such protein is not
reported in healthy individuals and those suffering from
goiter [85]. Despite the outstanding role of Fascin-1 in
increasing the invasion and cellular movement, available
studies have failed to link any genetic mutation with the
increased expression responsible for the characteristic.
The regulatory region of these genes consists of 250 base
pairs and is located at the 5’-flanging end of the gene
[86]. Therefore, studying the genetic changes of the pro-
moter region of fascin-1 as one of the factors involved in
the regulation of gene expression and discovering the re-
lation between such mutations and the rate of metastasis
can pave the way for early diagnosis of those suffering
from metastatic thyroid cancer.
Conclusion
In the past decade, many studies have been conducted
on genetic changes and molecular biology of thyroid
cancer to improves the accuracy of diagnosis and the ef-
fectiveness of treatment modalities. From among them
the mutations and rearrangements of certain proto-
oncogenes as well transcription and metastatic factors
such as P53, RAS, RET, BRAF, PPARγ and Fascin are of
great importance. In view of the fact that the available
methods are not capable of diagnosing thyroid cancer in
early stages, detection of differentiated mutations may
be an effective method in this regard. It seems that in
various cancerous cells, there are different and very spe-
cial mechanisms for metastasis processes. Genetic stud-
ies can also help identify the reason behind changes
noted in the expression of suppressor genes or meta-
static activators in order to find effective solutions to
prevent malignant variants of these cancers.
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